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Background/purpose: Melatonin, an indoleamine secreted by the pineal gland, plays a key
role in regulating circadian rhythm. It has chronobiotic, antioxidant, anti-inflammatory
and free radical scavenging properties.
Methods: A conference in Rome in 2014 aimed to establish consensus on the roles of
melatonin in children and on treatment guidelines.
Results and Conclusion: The best evidence for efficacy is in sleep onset insomnia and delayed
sleep phase syndrome. It is most effective when administered 3e5 h before physiological
dim light melatonin onset. There is no evidence that extended-release melatonin confersd Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, Via
641400165; fax: þ39 0641400343.
Curatolo).
logy Society. Published by Elsevier Ltd. All rights reserved.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 1 2 2e1 3 3 123EpilepsyADHD
Autismadvantage over immediate release. Many children with developmental disorders, such as
autism spectrum disorder, attention-deficit/hyperactivity disorder and intellectual
disability have sleep disturbance and can benefit from melatonin treatment. Melatonin
decreases sleep onset latency and increases total sleep time but does not decrease night
awakenings. Decreased CYP 1A2 activity, genetically determined or from concomitant
medication, can slow metabolism, with loss of variation in melatonin level and loss of
effect. Decreasing the dose can remedy this. Animal work and limited human data suggest
that melatonin does not exacerbate seizures and might decrease them. Melatonin has been
used successfully in treating headache. Animal work has confirmed a neuroprotective
effect of melatonin, suggesting a role in minimising neuronal damage from birth asphyxia;
results from human studies are awaited. Melatonin can also be of value in the performance
of sleep EEGs and as sedation for brainstem auditory evoked potential assessments. No
serious adverse effects of melatonin in humans have been identified.
© 2014 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
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Melatonin is an endogenously produced indoleamine secreted
by the pineal gland. It is usually secreted during darkness and
its secretion is suppressed by light. It plays a key role in
regulating the circadian rhythm.1,2 Melatonin has many other
biological functions including chronobiotic and antioxidant
properties, anti-inflammatory effects, and free radical scav-
enging.3 It is critically involved in early development through
its direct effects on placenta, developing neurons and glia, and
its role in the ontogenetic establishment of diurnal
rhythms.4,5 Furthermore melatonin regulates the vigilance
states depending on the activated melatonin receptors (MT1,
MT2 or both); MT2 and MT1 receptors are mainly involved in
NREM and REM sleep, respectively.6
Several studies have demonstrated the key chronobiotic
role of melatonin as amodulator of the sleepewake rhythm; ithas both chronobiotic and hypnotic properties7 that influence
circadian rhythmicity and affect circadian rhythm sleep dis-
orders.8e10 Because of these strong chronobiotic and hypnotic
properties, melatonin can improve sleepewake rhythm dis-
turbances and decrease sleep latency in children with sleep
disorders, when it is administered at the right time and in the
right dose.7,9e12 As a result, it is one of the most commonly
used drugs by pediatricians for infants, children and adoles-
cents with sleep problems.13e16 A recent study carried out in
Norway showed that hypnotic drug use in young people 0e17
years old increased during the period 2004e2011, from 8.9 to
12.3 per 1000, mainly owing to doubling of melatonin use. The
hypnotic drug use peaked at 15 per 1000 among those aged
1e2 years and melatonin use increased steadily from 6 to 12
years of age. Summarising the results of this study, the au-
thors reported that melatonin was dispensedmore frequently
than any of the other hypnotic drugs.16
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 1 2 2e1 3 3124Melatonin is prescribed by pediatricians mainly for sleep
onset insomnia (89%), delayedsleepphasesyndrome (66%)and
night-timeawakenings (30%). It isprescribedboth for typically-
developing children and for children with developmental dis-
orders, including autism, developmental delay, ADHD, and
behavioral disorders.17 Although melatonin is widely used in
children and is currently recommended bymany practitioners
asa ‘‘natural sleepingaid’’due to itsendogenousorigin,17 there
are no clinical guidelines on how to prescribe melatonin in
children with different neurological disorders.
A European consensus conference was held in Rome on
October 4th 2014 with the aims of assessing the current role of
melatonin in childhood sleep disturbances and answering
some key questions, including those relating to the correct
dosage in infants, children and adolescents, timing of
administration, duration of the treatment, benefits and pit-
falls of immediate compared to controlled release, and pre-
dictors of response tomelatonin treatment. This paper reports
themain points discussed at this conference, startingwith the
physiology and pharmacokinetics of melatonin, followed by a
review of the use of melatonin in the most relevant neuro-
psychiatric disorders based on meta-analyses/systematic re-
views or individual studies. Finally, we provide consensus
recommendations for the use of melatonin in both typically
developing children and those with neuropsychiatric disor-
ders in daily clinical practice.2. Physiology
Night-time melatonin production during pregnancy increases
after 24 weeks gestation until term. The fetus receives mela-
tonin by rapid trans-placental transfer depending onmaternal
circadian secretion.18 In 1997 Sadeh studied 20 normal,
healthy infants for 1 week with actigraphy and determined
the levels of 6-sulphatoxymelatonin (aMT6s), a melatonin
metabolite.19 He identified two groups of infants: 1) infants
with “mature” secretion patterns (rise of aMT6s during the
evening hours and suppression during the morning); and 2)
infants with “immature” type, with flat distribution or rise of
melatonin during the earlymorning hours. Those infants with
the immature pattern showed a delayed peak of melatonin
that was associated with more fragmented sleep during the
night, suggesting that melatonin plays an important role in
the development of the sleepewake rhythm. Another recent
research study attempted to relate dim light melatonin onset
(DLMO) with sleep disturbances in toddlers. Toddlers with
later DLMO had later bedtimes, sleep onset times, mid-sleep
times, and wake times. This study highlighted the large
inter-individual differences in DLMO.20 Furthermore, morning
melatonin concentrations in infants showed a negative cor-
relation with nocturnal sleep duration and were associated
with early waking time.21
As well as being associated with sleep disturbance, Tau-
man et al. suggested that 6-sulfatoxymelatonin levels at 16
weeks of age were significantly lower in infants with
abnormal vs normal development at 3 and 6 months of age.22
No other significant relation was evident between 6-
sulfatoxymelatonin excretion and growth, perinatal compli-
cations or medical problems.Several studies have shown that melatonin concentrations
remain extremely low in the first 3 months and increase
abruptly after 3months of age.23,24 This effect could be related
to the fact that melatonin in human milk showed a clear
circadian curve but was immeasurable in all artificial milks,
and could contribute to the consolidation of sleepewake
rhythm of infants until the maturation of their own circadian
system. Furthermore, endogenous nocturnal levels of mela-
tonin show a strong age effect: they are much higher in chil-
dren than in adults, they decline with age from 210 pg/ml in
preschoolers (1e5 years of age) to 130 pg/ml in school-aged
children (6e11 years) and to 50 pg/ml in young adults.25 This
decrease is mainly related to an increase in body size rather
than to decreasing pineal secretion.263. Pharmacokinetics
As an exogenous compound, melatonin advances sleep onset
in patients with circadian rhythm sleep disorders i.e. delayed
sleep phase disorder, improving health status and decreasing
parental stress.7,9,27,28 Long term treatment is usually
needed.29,30
Melatonin is a peculiar drug because timing of its admin-
istration plays a critical role in the results of treatment. Ac-
cording to the melatonin phase-response curve of 0.5 mg
melatonin in adults, phase advances occur with from ±8 h
before DLMO to ±2 h after, with maximum effect at 3e5 h
before DLMO. When administered two or three hours after
DLMO, no effects or reverse effect can occur. The optimal
administration time is earlier for higher doses of melatonin.31
This information was not available when the European Food
and Safety Authority (EFSA) concluded incorrectly that mela-
tonin should be administered before desired bedtime.32,33
Furthermore, knowing DLMO helps to predict melatonin
treatment success: the earlier the melatonin is administered
before the DLMO the larger the phase-advance of sleep onset.
Within a window of 1e6 h before DLMO, each advance of
intake time of one hour resulted in an increase in effect on
sleep onset of 19 min.34 DLMO cannot be predicted by sleep
diary, actigraphy or polysomnography.31,35 It can, however, be
assessed easily in home situations bymeasuringmelatonin in
saliva.35,36 When measuring melatonin levels, children aged
6e12 yrs are invited to chew on a cotton plug for 1e2 min
hourly between 7 and 11 pm, whilst it is suggested that ado-
lescents do so between 8 and 12 pm. In cases with severe
delayed or advanced sleep phase disorder, saliva should be
collected at later or earlier times or hourly for 24 h35
Some pitfalls can be encounteredwhen interpreting DLMO.
It is advisable to measure DLMO before starting melatonin, to
prevent inappropriate timing or doses of melatonin treat-
ment.29,36 When DLMO is measured in patients who stopped
melatonin use 1e6 weeks before measuring DLMO, often
strange, zig-zag, melatonin curves are seen35 and DLMO
cannot be determined reliably. It is therefore recommended
that DLMO be measured before starting melatonin treatment.
The main action of exogenous melatonin in patients with
sleep onset insomnia and late DLMO is to “pull” at the advance
of the endogenous melatonin rhythm and with it the
sleepewake rhythm. There is no evidence that prolonging the
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 1 2 2e1 3 3 125presence ofmelatonin in the bloodstream is of value, implying
that there no evidence to indicate that extended-release
melatonin has advantages over immediate-release acting
melatonin. If maintenance of sleep is the main problem,
melatonin treatment usually is ineffective.4. Delayed sleep phase syndrome and
chronic sleep onset insomnia
Delayed sleep phase syndrome (DSPS) is a circadian rhythm
sleep disorder characterized by a rigid delay in the timing of
the major sleep period in relation to desired sleepewake
times. It is associated with a delayed 24-h melatonin rhythm,
possibly linked to a PER3 polymorphism.37e39 The etiology is
likely to be heterogeneous, including delayed circadian
timing, longer than normal circadian rhythm period, slower
accumulation in homeostatic sleep drive, increased sensi-
tivity to phase-delaying evening light, or an insensitivity to
resetting properties of morning light.40,41
Recentmeta-analyses have indicated thatmelatonin is and
effective and apparently safe for treatment of primary sleep
disorders or DSPS in children.9,42,43 However, the effects
probably vary from patient to patient because of inter-
individual differences in etiology. Another aspect to influ-
ence variation in effect is the timing of intake in reference to
endogenous circadian rhythm, as explained earlier. There are
currently six published randomized controlled trials (RCTs) on
melatonin treatment for primary DSPS or chronic sleep-onset
insomnia in children and adolescents.10,27,44e47 Sleep phase
advanced in all but one study.47 Sleep length increased in two
studies but did not change significantly in two other
studies.27,47 Daytime sleepiness improved in one study,45 but
not in another study,46 and health status and functional status
was improved in one study.27 Two studies showed no signif-
icant effects on various tests of cognitive performance.27,46
The dose of melatonin varied from 1 to 5 mg/night. A dose-
finding study with melatonin 0.05 mg/kg, 0.1 mg/kg, 0.15 mg/
kg and a placebo group10 showed advanced sleep onset time
(SOT) and DLMO by approximately 1 h and decreased sleep
onset latency (SOL) by 35 min; these effects were significantly
different from placebo. No significant differences were found
between the three melatonin doses. Several studies have
shown that effects on SO, SOL, andDLMO increasewith earlier
circadian administration time. Adverse events were mild. In
two studies, adverse events occurred only with melatonin
treatment,44,45 but in two other studies adverse events
occurred in both the melatonin and in the placebo groups.10,27
When melatonin was administered at a time related to
DLMO,meta-analyses showed thatmelatonin decreased sleep
onset latency.9,48 However, in the meta-analysis of melatonin
administration without knowing DLMO, melatonin did not
improve sleep.49 This difference in results might be ascribed
to the difference in melatonin administration strategy; how-
ever, other factors might also be involved, such as differences
in primary diagnosis. For example, the study by Buscemi et al.
showed much more pronounced effects with DSPS than with
insomnia.
Melatonin treatment for primary DSPS or chronic sleep
onset insomnia in children and adolescents advancessleepewake rhythm and DLMO, possibly lengthens sleep, and
appears to be safe both in the short term and in the long
term. More studies are needed to evaluate the effects on day-
time sleepiness and health/behavior/cognition, particularly in
adolescents, given the high prevalence of DSPS in this
population.
No specific studies on the use of melatonin in infants with
insomnia have been reported. However, a recent survey re-
ported that the melatonin dose administered in infants
ranged from 0.5 to 3.5 mg (mean 2.1 mg), in children from 1 to
10mg (mean 3.5mg) and in adolescents from 2 to 12mg (mean
5.3mg).Maximumprescribed doseswere 5mg (infants), 10mg
(children) and 18 mg (adolescents) with a wide range. The
most commonly reported starting dose was 3 mg. Duration of
treatment ranged from 0 to 200 weeks, with an average of 16.5
weeks (SD 26.3 weeks).175. Melatonin in neuropsychiatric disorders
5.1. Attention-deficit/hyperactivity disorder (ADHD)
Asmany as 70% of children with ADHD have been reported as
having mild to severe sleep problems. The most recent meta-
analysis of sleep disturbances in ADHD, focused on children
and adolescents, found significantly more sleep problems in
children with ADHD than a normal comparison group, based
upon subjectively-rated sleep items, including bedtime resis-
tance, sleep onset difficulties, night awakenings, difficulties
with morning awakenings, sleep disordered breathing, and
daytime sleepiness.50 The meta-analysis also indicated that
children with ADHD were significantly more compromised
than the comparison group with regard to several parameters
assessed with objective methods (PSG or actigraphy), such as
sleep onset latency (on actigraphy), the number of stage
shifts/hour of sleep, the apneaehypopnea index, sleep effi-
ciency on polysomnography, true sleep time on actigraphy,
and average times to fall asleep on the Multiple Sleep Latency
Test. These results indicated that children with ADHD had
higher levels of daytime sleepiness. Sleep onset insomnia is
arguably the most commonly reported problem.51 The causes
of sleep onset insomnia in children with ADHD are likely to be
heterogeneous and multifactorial.52 Currently, there is no
established consensus on how to treat sleep disorders in
ADHD and the grade of available empirical evidence is
generally low. Melatonin may be an option, at least when
sleep onset insomnia is related to a delayed sleep phase dis-
order.53 There is initial evidence that the use of melatonin in
children with ADHD and sleep disturbance is grounded on a
pathophysiological rationale, since a delay in dim-light
melatonin onset (DLMO) has been reported in children with
ADHD and sleep onset insomnia.54 In addition, melatonin
genetic pathways have been found to be abnormal in children
with ADHD.55
In a systematic review of the literature, searching Pubmed,
Ovid and Web of Knowledge databases (to September 29th,
2014), performed in preparation for the European Consensus
meeting, we found a total of five trials ofmelatonin in children
with ADHD, including 3 RCTs (two rated at “low risk” of bias
and 1 at “uncertain risk” by means of the Cochrane tool of
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 1 2 2e1 3 3126bias).56 All these trials concurred in showing that melatonin
given in doses ranging from 3 to 6 mg/night) significantly
reduced sleep onset delay and increased total sleep duration,
but did not impact on daytime ADHD core symptoms asmight
have been expected, considering that better sleep quantity/
quality has been related to improvement in cognitive and
behavioral functioning.57 This last findingmight be accounted
for by the short duration of most of the available trials that is
below 3 months,58e61 with only one long-term study (mean
follow-up: 3.7 years).29 In these studies, melatonin was
generally well tolerated both in the short term and in the long
term. Most of the participants who discontinued treatment
did so because sleep problems were no longer a major issue
rather than because of intolerable treatment effects. Adverse
events included sleep maintenance insomnia, excessive
morning sedation, low mood and headache, profuse perspi-
ration and “daytime laziness”.
5.2. Autism spectrum disorders (ASD)
Sleep disturbances such as reduced total sleep and longer
sleep latency, as well as nocturnal and early morning awak-
enings, are commonly observed in population studies of in-
dividuals with ASD, with prevalence estimates ranging from
30 to 53%, depending on study design and definition of sleep
problems.62,63 Sleep problems can worsen the symptoms of
autism and can result in challenging behaviors. Abnormalities
in daytime or night-time values of melatonin compared to
typically-developing controls have been often reported64,65
suggesting that melatonin supplementation might be effec-
tive in improving sleep parameters in children with ASD.
Furthermore, gene abnormalities that could contribute to
decreased melatonin production have been reported in a
subgroup of children with ASD and comorbid sleep onset
delay.66
A meta-analysis of randomized double-blind placebo-
controlled crossover studies showed significant improve-
ments with large effect size in sleep duration and sleep onset
latency, but not in night-time awakenings in individuals with
ASD who took melatonin.67 Children with ASD and insomnia
who are responsive to low dose of melatonin, have been
shown to present with relatively normal profiles of endoge-
nous and supplemental melatonin.65 Patients in whom the
effect of melatonin disappeared have been shown to be
CYP1A2 poor metabolizers due to a single nucleotide poly-
morphism (SNP) in the CYP1A2 gene.68 The majority of chil-
dren with ASD responded to a dose of 1e3 mg given 30 min
before bedtime, with improvement in sleep latency and total
sleep duration.67,69 The overall improvement rate with mela-
tonin was 80%. Melatonin was well tolerated with minimal
adverse effects.67
Melatonin is of special interest in ASD, in view of the re-
ported abnormalities in central and peripheral serotonin
neurobiology70,71; however, the relationship between mela-
tonin and serotonin needs to be clarified in children with ASD
and comorbid sleep disorders. Further research into the sleep
problems of people ASD is required both to elucidate the
mechanism of action of supplemental melatonin and to
identify which individuals are most likely to benefit from
melatonin treatment.5.3. Neurodevelopmental disabilities (NDD)
Sleep problems are reported to occur in 13e86% of individuals
with NDD, depending on study design, participant character-
istics, and definition of sleep problems. Such problems are
often complex and usually more difficult to treat than in in-
dividuals without NDD. Melatonin is used widely in children
with insomnia andNDD, because of its apparently safe profile,
but there are no specific clinical guidelines on how to pre-
scribe melatonin in this group of children.72
Ameta-analysis of nine of randomized, placebo-controlled
trials, including a total of 183 individuals with NDD, showed
that melatonin decreased sleep latency by a mean of 34 min,
increased total sleep time by a mean of 50 min and less
significantly decreased the number of awakenings per night.11
A recent placebo-controlled study in 146 children (age 3e15
years) with intellectual disability showed similar results.73 In
some patients with NDD and sleep problems, the initial good
response to melatonin disappeared within a few weeks of
starting treatment and the good response returned only after
considerable dose reduction.11 The loss of efficacy of mela-
tonin treatment after an initial good response is a major
problem possibly caused by slow metabolism because of
decreased activity of the CYP1A2 enzyme.74 This may result in
increasing daily melatonin levels. Consequently melatonin
levels accumulate and after some time the circadian mela-
tonin rhythm is lost. This loss of circadian rhythm might
explain why exogenous melatonin loses its effectiveness.
If themelatonin dose is high and/or the individual is a poor
metabolizer, high daytimemelatonin levelsmay result. Braam
(personal communication) analyzed daytimemelatonin levels
in 150 patients who visited a sleep clinic between 2009 and
2014. Of the 150 patients, 74 were already taking melatonin at
the first visit and 76were not takingmelatonin. In 58 (78.4%) of
those who had already been taking melatonin, the daytime
melatonin levels in saliva were extremely high (>50 pg/ml),
whereas daytime melatonin levels in 72 of 76 those who had
not already been takingmelatonin users (95%) were <10 pg/ml
(W. Braam, personal communication). In 40 out of 76 non-
melatonin users at first visit (52.8%) a loss of effect and high
daytime melatonin levels after 4e12 weeks of melatonin
treatment (0.5 e 3 mg) were observed. This loss of effect may
be linked to the decreased activity of the CYP1A2 enzyme that
resulted in slow melatonin metabolism; slow melatonin
metabolizers have been reported as being 12%e14% of the
general population, but might bemuch higher in persons with
NDD.68
Melatonin has been also used in clinical practice to treat
severe sleep problems associated with various genetic syn-
dromes (Table 1). In two genetic syndromes severe sleep
problems are included in the diagnostic criteria and are
related to melatonin disturbance. Smith Magenis syndrome is
characterized by daytime somnolence, night waking and early
waking caused by an inversed circadian melatonin
rhythm.75,76 Recommended treatment includes a combination
of melatonin inhibition by acebutolol (10 mg/kg in one early
morning dose) and evening melatonin supplementation (no
dose guidelines). Children with Angelman syndrome may
present with sleep onset insomnia as well as sleep mainte-
nance problems.77 Melatonin levels are low and melatonin
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studies. The melatonin dose should be low (0.3 mg) because
the prevalence of slow melatonin metabolisers in Angelman
syndrome is very high. Tuberous Sclerosis Complex (TSC) can
be associatedwith different types of sleep disorders, including
multiple night awakenings and reduced total sleep time.78
Melatonin has been shown to reduce SOL and improve total
sleep time79,80 in patients with TSC. Melatonin was also re-
ported to reduce sleep problems in children with Rett syn-
drome81,82 and Sanfilippo syndrome (mucopolysaccharidosis
type III).83,846. Melatonin in other neurological disorders
6.1. Epilepsy
Because a high proportion of children with neuro-
developmental disorders have sleep problems and either have
or develop epilepsy, there is great interest in determining
whether melatonin is liable to exacerbate or precipitate sei-
zures. The increased prevalence of sleep disorders in children
with NDD has been discussed earlier. The prevalence of epi-
lepsy in NDD depends on the type of the disorder and the
severity of any intellectual disability. For example, in ASD, the
prevalence of epilepsy is much higher than in the general
population. Woolfenden et al.85 carried out a systematic re-
view on outcomes of children with autism. They estimated
from two studies of children with autism for whom the age at
follow up was under 12, and in whom the majority did not
have intellectual disability (mental retardation), that the rate
of epilepsy was 6.1% (95% confidence interval 3.8%e9.0%); in
nine studies in which the majority of subjects did have intel-
lectual disability and the age at follow-up was 12 years or
more, the pooled percentage estimates of those having epi-
lepsy at follow-up was 23.7% (95% confidence interval
17.5e30.5%) In a double-blind placebo controlled crossover
trial of the effect of melatonin on seizures of 12 patients with
uncontrolled epilepsy, Goldberg-Stern observed a statistically
significant reduction in diurnal seizures.86 However, in sub-
sequent reviews it was concluded that it was not possible to
draw any definitive conclusion about the role of melatonin in
reducing seizures frequency or improving quality of life in
people with epilepsy.87,88 There is no clear evidence that
melatonin exacerbates seizures. The very limited number of
randomized controlled trials and more extensive animal data
not only suggest that melatonin is unlikely to exacerbate
seizures but indicate that it might even protect against them,
although the data are too sparse to allow firm conclusions to
be drawn.
6.2. Headache
Melatonin can have a role in both biological regulation of sleep
and headache. A strict relationship between sleep and head-
ache has been recognized for a long time. Melatonin may play
a role in headache pathophysiology via several mechanisms.
The antinociceptive effects of melatonin have been demon-
strated in animal models, both in inflammatory and neuro-
pathic pain.89,90 Melatonin interacts with a number receptor
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serotonergic, a1-adrenergic, a2-adrenergic and most impor-
tantly MT1/MT2 melatonin receptors present in the dorsal
horn of the spinal cord, as well at multiple central nervous
system levels (hypothalamus, hippocampus, medulla oblon-
gata, pons and retina).90 Because of its ability to scavenge toxic
free radicals, melatonin can reduce macromolecular damage
in all organs. Melatonin also reduces the up-regulation of a
variety of pro-inflammatory cytokines, interleukins and TNF-
alfa.90 Melatonin has been shown to reduce transendothelial
cell migration and oedema; it is involved in membrane sta-
bilization, as well as inhibiting the activity of nitric oxide
synthase. It can decrease dopamine and glutamate release; it
can also potentate the receptor-mediated response of GABA
and the opioid immune response.91,90
Melatonin might regularize the sleepewake pattern
through its “chronobiological” and “sleep-hygiene ef-
fects”.92,93 Adequately timed and dosed melatonin treatment
decreased headache in 78.6% of 328 patients with circadian
rhythm sleep disorders and headache, while adequately
timed and dosed melatonin induced (slight) headache in
13.8% of 676 patients with circadian rhythm sleep disorders
without headache.94 Individuals with migraine report a high
prevalence of sleep disturbances in parents, and sleep dis-
turbances in infancy, as well as an elevated level of famil-
iarity of migraine, suggesting a genetic link between
headache and sleep disorders.95 An alteration of serotonergic
and dopaminergic neurotransmitter pathways could predis-
pose to both these disorders at different ages: earlier for sleep
disorders and later for headache, as consequence of such a
neurotransmitter imbalance.95 In an open-label trial in chil-
dren with primary headache, melatonin 3 mg twice daily
reduced the number (by more than 50%), intensity and
duration of headache attacks in 14 of 21 children.96 A
decrease in nocturnal melatonin secretion has also been
identified in patients with cluster headaches. A study of
melatonin in a single dose of 0.3 mg/kg for three months
indicated that melatonin might be considered as an effective
and safe drug in the prophylaxis of migraine in children.97
However, these studies have several limitations. In partic-
ular, small samples were investigated. There is still no
definitive consensus about the therapeutic use of melatonin
for headache in children.7. Neuroprotective effects of melatonin
Birth asphyxia in term newborn infants remains a significant
problem throughout the world, contributing to
510,000e717,000 neonatal deaths, 1.15 million new cases of
neonatal encephalopathy and 413,000 impaired survivors,98
which may suffer from long-term neurological conse-
quences such as cerebral palsy, mental retardation and epi-
lepsy. To date, therapeutic hypothermia is the only clinical
intervention that has shown to be effective in reducing brain
damage in asphyxiated babies; however infants treated with
hypothermia may have adverse outcomes, implying that
there is a need for new and more effective treatments to
provide safe and successful neuroprotection against neonatal
encephalopathy.Optimizing therapy for neonatal brain injury requires capi-
talizing on multiple pathways. Experimental evidence has
demonstrated the multiple neuroprotective benefits of mela-
tonin, such as reducing infarct volume and neuronal loss,
minimizing lipid and protein peroxidation, inhibiting free
radical production, blocking apoptosis and decreasing inflam-
mation.99 Indeed, its benign safety profile and relative ease of
administration to both fetus and neonate make melatonin an
attractive emergingneuroprotective agentwith strongpotential
for clinical translation.Ashypoxic-ischemicbrain injury isoften
unpredictable, one of the key challenges for a new intervention
strategy is to be able to ameliorate ongoing or secondary injury,
by being administered as a post-insult therapy.
In animal studies, melatonin has been shown to be pro-
tective when given to neonatal rats 5 min after the injury and
repeated 24 and 48 h later, reducing the percentage of ipsi-
lateral damage and decreasing behavioral asymmetry and
learning deficits, with long-lasting benefit.100 Melatonin has
also been shown to maintain the number of well-preserved
neurons after the injury, an effect related to reduction in
delayed cell death and reactive astrogliosis and also to the
maintenance ofmyelination.101 In addition, Robertson et al.102
showed that melatonin augmented hypothermic neuro-
protection by improving cerebral energy metabolism, as
indicated by magnetic resonance spectroscopy biomarkers,
and reducing cell death across the brain.
The prevention of neurological disabilities following pre-
term birth remains a major public health challenge. Various
experimental studies have tested the neuroprotective effects
of antenatal and postnatal melatonin administration in
different animal models (e.g. rat, mouse, sheep, and pig) of
brain lesions mimicking the lesions observed in human neo-
nates.103 These data strongly emphasize the neuroprotective
properties of melatonin, whatever animal species has been
used and in several types of brain damage across various
developmental stages.104
The fact that melatonin easily crosses the placental barrier
and can therefore be administered antenatally is a powerful
argument for researching its use in minimizing, if not pre-
venting, brain lesions in human subjects. Even though the
dose and timing for optimal neuroprotection remain to be
elucidated, all these data, along with the apparently benign
safety profile and relative ease of melatonin administration,
have favored the consideration of some small phase I and II
clinical studies, the results of which should provide further
relevant information about the real potential of melatonin for
clinical translation.8. Melatonin as pre-medication for
neurologic diagnostic procedures
Melatonin has been used as a sleep inducing agent in neuro-
physiological and neuroimaging procedures in child neurology.
Obtaining sleep to record EEG in childhood is of major impor-
tance because sleep can activate epileptiform abnormalities,
thus helping clinicians to achieve a more accurate electro-
clinical assessment.105 However, sleep deprivation, which is
usually necessary to make the child fall asleep in the EEG lab-
oratory, can be difficult and burdensome for the family,
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 9 ( 2 0 1 5 ) 1 2 2e1 3 3 129especially in the case of challenging children. If spontaneous
sleep is difficult to achieve, sedative drugs can be used. How-
ever, in the last two decades, melatonin has been used widely
to induce sleep for EEG recording, initially in adults, and sub-
sequently in children. When melatonin is administered, the
yield of epileptiform abnormalities is similar to that reported
for sleep-deprived EEGs, underlining that melatonin adminis-
tration does not interfere with EEG interpretation nor does it
hide epileptiform abnormalities.106 Melatonin, administered at
different doses ranging from 2 to 20 mg, was able to induce
sleep in a high percentage of children (79e88%), reducing sleep
onset latency; sleep duration was usually brief, but sufficient
for an adequate EEG recording, and was rarely associated with
mild somnolence after the exam.105e108
Melatonin has also been used to induce sleep as an alter-
native to sedation for performing brainstem auditory evokedTable 2 e Recommendations for prescribing melatonin in child
insomnia.
Consider melatonin treatment in children with sleep
onset problems and/or difficulty waking up in the
morning at conventional times.
Usually melatonin is not effective for sleep
maintenance problems.
Measure DLMO (if possible).
Minimum age for administration No studies r
been used in
effects we ca
be quite safe
Time of administration in children If used as ch
When DLMO
onset time
If used as sle
Dosage If used as chr
e4 h before
3 mg; adoles
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When 1 mg
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examination
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peculiar neu
month
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Whenmelatonin treatment is not effective (anymore): Check timin
Be aware tha
melatonin m
Reconsider d
together wit
For very seve
Comedicatio
 Metabolism
 Metabolism
In some case
If sleep maintenance problems after start melatonin
treatment:
Melatonin dopotentials,109,110 and for successfully performing brain mag-
netic resonance imaging (MRI) in about half of the
patients.111,1129. Adverse effects of melatonin
No serious safety concerns have been attributed to melatonin
use in children. Systematic reviews showed that for sleep
disorders such as jet lag and shift work, melatonin appears to
be is safe for short-term and long-term use.42,49 Rossignol and
Frye (2011) stated that no adverse effects were reported with
the use ofmelatonin in childrenwithASD in 7 of the 12 studies
included in their meta-analysis.67
The most frequently reported side effects associated with
melatonin use in children include morning drowsiness,ren with sleepewake rhythm disorders or sleep onset
eported the minimum age for administering melatonin. Since it has
high dosage in infants to prevent neuronal injuries without side
n expect that melatonin administration after 6 months of age could
ronobiotic, 2e3 h before DLMO
cannot bemeasured: administer melatonin 3e4 h before actual sleep
ep inductor 30 min before bedtime
onobiotic, start with a low dose of 0.2e0.5mg fast releasemelatonin 3
bedtime; increase by 0.2e0.5 mg every week as needed (maximum
cents: 5 mg) until effect
e after 1 week: increase dose by 1 mg every week until effect appears
is effective: try lower dose
ose: <40 Kg: 3 mg; >40 Kg: 5 mg
leep inductor start with 1e3 mg 30 min before sleep of before the
(EEG, Evoked potentials or MRI)
uration should be tailored to the specific patient in relation to the
rodevelopmental disabilities but in general should be not less than 1
an be withdrawn just before puberty (age around 12 yrs) or shortly
(18e24 yrs)
cessful treatment too early (i.e. 4 weeks after its start) may results in
e of insomnia
in treatment once a year during one week (preferably in summer)
al sleep cycle is established
g of administration: melatonin intake time may be shifted to too late
t loss of efficacy of melatonin treatmentmost likely is caused by slow
etabolism
iagnosis: look for neuropsychiatric comorbidity and treat that
h the insomnia
re delayed sleep wake rhythm: consider chronotherapy
n can influence melatonin metabolism:
slower: oral contraceptives, cimetidine, fluvoxamine
faster: carbamazepine, esomeprazole, omeprazole
s dose reduction is warranted instead of dose escalation
se is probably too high
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hypothermia.73,113,114 Slight transient headache and gastro-
intestinal symptoms are mainly reported during the first
days of the treatment.115 In elderly the administration of 3 mg
of melatonin induced hypothermia and plasma melatonin
elevated into the daylight hours.116
Effects of the melatonin on human reproduction117 and in
auto-immune disorders118 remain unclear. No melatonin-
associated alterations of laboratory values were noted.119
Since melatonin is primarily metabolized by CYP1A2 and
CYP2C19, inhibitors of CYP1A2 (e.g., tricyclic antidepressants,
fluvoxamine, cimetidine) may increase melatonin concen-
trations.120 Because melatonin may decrease blood pressure
or serum glucose, particular attention should be given in pa-
tients who receive concomitant therapy with agents that
affect blood pressure or serum glucose.121
In supporting the safety of melatonin it should be noted
that melatonin has been administered in very high doses to
animals (from 5 to 20 mg/kg and even >100 mg) without
adverse effects but has shown neuroprotective properties.
The lethal dose in animals has yet to be determined, with the
implication the high doses administered so far have not been
lethal. However, these data cannot be taken as assurance that
melatonin can be administered in infants and children at high
doses without adverse effects.10. Clinical recommendations
As evident from the previous sections, the dose, timing and
modalities of administration of melatonin vary considerably
across studies. Table 2 presents the consensus of the authors
regarding the use of melatonin in infants and children with
sleepewake rhythm disorders or sleep onset insomnia. It
must be emphasized that these represent general recom-
mendations that need to be tailored to each individual.
So far, the best evidence for the indication of melatonin
treatment in children is for insomnia caused by circadian
rhythm sleep disorders. Because insomnia due to other situa-
tions and disorders, including bad sleep hygiene, ADHD/ADD,
personality disorders and depression, can mimic insomnia
caused by circadian rhythm sleep disorders, the diagnosis
should be only be made after careful clinical assessment and
possibly measuring DLMO. There is a strong argument for
determining DLMO, not only for an optimal diagnosis, but also
for optimal melatonin treatment, as melatonin is most effec-
tive when it is administered 3e5 h before DLMO in children
with sleep onset insomnia and late DLMO. DLMO can be
measured relatively easily by collecting saliva at home. DLMO
measurements contribute substantially both to optimal diag-
nosis and treatment of patients with chronic insomnia.11. Conclusions and future directions
Melatonin can be effective not only for primary sleep disor-
ders but also for sleep disorders associated with several
neurological conditions. Controlled studies on melatonin for
sleep disturbance in children are needed since melatonin is
very commonly prescribed in infants, children andadolescents, and there is a lack of certainty about dosing
regimens. The dose of melatonin should be individualized
according to multiple factors, including not only the severity
and type of sleep problem, but also the associated neurolog-
ical pathology. Future controlled clinical studies should clarify
the possible neuroprotective role of melatonin administration
in infants with hypoxic-ischemic encephalopathy. Because of
the lack of research and controlled trials, there is a pressing
need for studies on melatonin in infants and children with
sleep disorders, to identify those who will benefit from
melatonin treatment and to determine the doses appropriate
for the severity and type of disorder.Conflict of interest
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